Results 261 to 270 of about 87,437 (368)

Similar response rates and superior early progression‐free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma [PDF]

, 2005
John Kuruvilla, Tracy Nagy, Melania Pintilie, Richard Tsang, Armand Keating, Michael Crump   +5 more
openalex   +1 more source

Mitoxantrone liposome-based MEA regimen for treatment mixed lineage leukemia-rearranged acute myeloid leukemia: a case series. [PDF]

AME Case Rep
Guo H, Ye S, Zhang J, Zhao S, Wang J, Xu J, Wang L, Xue H.   +7 more
europepmc   +1 more source

Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells [PDF]

, 2005
Kyrjon van Pelt, Gerald de Haan, Edo Vellenga, Simon Daenen   +3 more
openalex   +1 more source

Neurological manifestations of chronic graft versus host disease

Internal Medicine Journal, Volume 55, Issue 10, Page 1639-1646, October 2025.
Abstract Introduction Allogeneic haemopoietic stem cell transplant (allo‐HSCT) is an established therapy for many malignant and non‐malignant conditions, with an increasing number of uses and indications in recent decades. Complications including graft versus host disease (GvHD) carry significant morbidity and mortality.
Tal Koren, Alice Kwok, William Stevenson, Kate Ahmad, Joseph Nogajski, John Parratt, Ian Kerridge, Karl Ng   +7 more
wiley   +1 more source

Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025. [PDF]

Cancer J
Socal MP, Acha J, Yang CY, Sun Y, Dada M, Dai T, Anderson G, Ballreich J.   +7 more
europepmc   +1 more source

Veno‐occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine [PDF]

, 2005
Anna Boula, Elpis Mantadakis, Irini Xilouri, Anna Christoforidou, Andreas Foudoulakis, George Samonis   +5 more
openalex   +1 more source

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

Nature Network Boston, 2017
N. Herold, Sean G. Rudd, L. Ljungblad, Kumar Sanjiv, I. H. Myrberg, Cynthia B. J. Paulin, Y. Heshmati, A. Hagenkort, J. Kutzner, B. Page, J. Calderón-Montaño, O. Loseva, A. Jemth, L. Bulli, Hanna Axelsson, B. Tesi, Nicholas C. K. Valerie, A. Höglund, Julia Bladh, Elisée Wiita, M. Sundin, M. Uhlin, G. Rassidakis, M. Heyman, K. P. Tamm, Ulrika Warpman-Berglund, J. Walfridsson, S. Lehmann, D. Grandér, T. Lundbäck, P. Kogner, J. Henter, T. Helleday, T. Schaller   +33 more
semanticscholar   +1 more source

Daratumumab for CD20−CD38+ Relapsed/Refractory Diffuse Large B‐Cell Lymphoma

Journal of Cellular and Molecular Medicine, Volume 29, Issue 20, October 2025.
ABSTRACT Patients with R/R DLBCL (relapsed/refractory diffuse large B‐cell lymphoma) treated with rituximab‐based regimens often have a reduction in the expression level of CD20. Replacement of target proteins for new targeted chemotherapy has become a popular direction for the treatment of R/R DLBCL.
ZeTong Hong, ZhaoYang Hong, YaXian Ma, Qing Yin, Min Liu, Wei Huang, KuangGuo Zhou, Dan Li, TongJuan Li, Miao Zheng   +9 more
wiley   +1 more source

Intermediate-dose cytarabine alone versus combination in consolidation therapy for non-transplant acute myeloid leukemia: a retrospective study. [PDF]

Ann Med
Liu Y, Wang Z, Chen T, Zhou L, He Q, Deng X, Long K, Zou X.   +7 more
europepmc   +1 more source

Total body irradiation (TBI) and G-CSF-combined high-dose cytarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) and advanced myelodysplastic syndrome (MDS) [PDF]

, 2005
Takehiko Mori, Akira Yokoyama, Yoshinobu Aisa, Akiko Yamane, Rie Yamazaki, Tomonori Nakazato, Y. Ikeda, Shinichiro Okamoto   +7 more
openalex   +1 more source